NIFRAMYCINE HYDROCORTISONE
LAD
Identification
- Active ingredient (INN)
- FRAMYCETINE**/HYDROCORTISONE (SOUS FORME DE FRAMYCETINE SULFATE/HYDROCORTISONE)
- Internal code
- 22 E 015
- Country of Origin
- Algeria
- Pharmaceutical form
- Nasal Solution
- Prescription List
- Highly Regulated (List I)
- Packaging
- flacon./15ml
DAWA Clinical Workbench v2.0
Information may not be accurate. Always consult a physician, pharmacist, or specialist before acting on any data shown here.
Description
A component of neomycin that is produced by Streptomyces fradiae.
On hydrolysis it yields neamine and neobiosamine B. (From Merck Index, 11th ed).
Indications
For the treatment of bacterial blepharitis, bacterial bonjunctivitis, corneal injuries, corneal ulcers and meibomianitis.
For the prophylaxis of ocular infections following foreign body removal
Pharmacodynamics
Framycetin is used for the treatment of bacterial eye infections such as conjunctivitis.
Framycetin is an antibiotic.
It is not active against fungi, viruses and most kinds of anaerobic bacteria.
Framycetin works by binding to the bacterial 30S ribosomal subunit, causing misreading of t-RNA, leaving the bacterium unable to synthesize proteins vital to its growth.
Framycetin is useful primarily in infections involving aerobic bacteria bacteria.
Mechanism of Action
16S ribosomal RNA (Enteric bacteria and other eubacteria) Inhibitor Small ribosomal subunit protein uS12 (Escherichia coli (strain K12)) Inhibitor.
Adverse Effects
Improve decision support & research outcomes With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
View sample adverse effects data in our new Data Library! See the data Improve decision support & research outcomes with our structured adverse effects data.